Increased risk of hospitalization for acute lower respiratory tract infection among australian indigenous infants 5-23 months of age following pneumococcal vaccination: A cohort study

Kerry-Ann O'Grady, Katherine Lee, John Carlin, Paul Torzillo, Anne Chang, Edward (Kim) MULHOLLAND, Stephen B Lambert, Ross Andrews

    Research output: Contribution to journalArticle

    Abstract

    Background: Australian Indigenous children are the only population worldwide to receive the 7-valent pneumococcal conjugate vaccine (7vPCV) at 2, 4, and 6 months of age and the 23-valent pneumococcal polysaccharide vaccine (23vPPV) at 18 months of age. We evaluated this program's effectiveness in reducing the risk of hospitalization for acute lower respiratory tract infection (ALRI) in Northern Territory (NT) Indigenous children aged 5-23 months. 

    Methods: We conducted a retrospective cohort study involving all NT Indigenous children born from 1 April 2000 through 31 October 2004. Person-time at-risk after 0, 1, 2, and 3 doses of 7vPCV and after 0 and 1 dose of 23vPPV and the number of ALRI following each dose were used to calculate dose-specific rates of ALRI for children 5-23 months of age. Rates were compared using Cox proportional hazards models, with the number of doses of each vaccine serving as time-dependent covariates. 

    Results: There were 5482 children and 8315 child-years at risk, with 2174 episodes of ALRI requiring hospitalization (overall incidence, 261 episodes per 1000 child-years at risk). Elevated risk of ALRI requiring hospitalization was observed after each dose of the 7vPCV vaccine, compared with that for children who received no doses, and an even greater elevation in risk was observed after each dose of the 23vPPV (adjusted hazard ratio [HR] vs no dose, 1.39; 95% confidence interval [CI], 1.12-1.71; P = .002). Risk was highest among children vaccinated with the 23vPPV who had received <3 doses of the 7vPCV (adjusted HR, 1.81; 95% CI, 1.32-2.48). 

    Conclusions: Our results suggest an increased risk of ALRI requiring hospitalization after pneumococcal vaccination, particularly after receipt of the 23vPPV booster. The use of the 23vPPV booster should be reevaluated. 
    Original languageEnglish
    Pages (from-to)970-978
    Number of pages9
    JournalClinical Infectious Diseases
    Volume50
    Issue number7
    DOIs
    Publication statusPublished - 1 Apr 2010

    Fingerprint Dive into the research topics of 'Increased risk of hospitalization for acute lower respiratory tract infection among australian indigenous infants 5-23 months of age following pneumococcal vaccination: A cohort study'. Together they form a unique fingerprint.

  • Cite this